TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
QURE

Uniqure NV

Healthcare · Biotechnology

38.20$ -0.2% vs. previous close Closing price · As of: Sep 25, 2026

Ownership

Ownership Structure

Who owns Uniqure NV (QURE)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 82.9% of the shares are freely tradable; institutional investors hold 84.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 84.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 1.3%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 82.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 14.4%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 69Mio.

Largest Shareholders

Institutions

Institutions QURE
Name Stake (%) Shares Change (%) Date
venBio Select Advisor LLC 8.59 5,959,595 -3.1 03/31/2026
Aberdeen Group PLC 4.11 2,848,117 -46.3 06/30/2026
JPMorgan Chase & Co 4.09 2,837,466 -3.3 03/31/2026
RTW INVESTMENTS, LLC 3.73 2,586,356 -30.3 03/31/2026
State Street Corp 3.26 2,260,512 -30.0 03/31/2026
Orbimed Advisors LLC 3.08 2,136,149 +189.7 03/31/2026
FMR Inc 2.51 1,743,808 -72.1 03/31/2026
BlackRock Inc 2.50 1,733,458 -12.2 03/31/2026

Funds

Funds QURE
Name Stake (%) Shares Change (%) Date
State Street® SPDR® S&P® Biotech ETF 3.64 2,524,656 -1.1 08/31/2026
JPMorgan Growth Advantage A 2.55 1,771,632 +43.1 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?